Michael Misuraca, DO
Nephrology · Livonia, MINPI 1982826699
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Vifor Pharma, Inc.$1K
- Travere Therapeutics, Inc.$854
- Otsuka America Pharmaceutical, Inc.$818
- Amgen$717
- Bayer$694
- plus $5K from 22 others
What the payments were for
- Food & beverage$9,95196%
- Education$4444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 49 | $1,422 |
| Vifor Pharma, Inc. | 60 | $1,316 |
| Travere Therapeutics, Inc. | 28 | $854 |
| Otsuka America Pharmaceutical, Inc. | 25 | $818 |
| Amgen(2 entities) | 15 | $717 |
| Bayer | 23 | $694 |
| Mallinckrodt Hospital Products Inc. | 14 | $519 |
| Aurinia Pharma U.S., Inc. | 18 | $512 |
| Akebia Therapeutics Inc | 19 | $437 |
| Calliditas Therapeutics US Inc. | 11 | $399 |
| Boehringer Ingelheim | 15 | $328 |
| OPKO Pharmaceuticals, LLC | 18 | $310 |
| GSK | 10 | $305 |
| Mallinckrodt Enterprises LLC | 10 | $302 |
| Fresenius USA Marketing, Inc. | 17 | $296 |
| Sanofi | 8 | $280 |
| Novo Nordisk | 2 | $242 |
| Novartis | 11 | $203 |
| Ardelyx, Inc. | 6 | $147 |
| Lundbeck LLC | 3 | $130 |
| Apellis Pharmaceuticals, Inc. | 2 | $46 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Nxstage Medical, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,395 in reported general payments places this provider in the 90th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 12 | $236,893 |
| FarxigaDapagliflozin Propanediol | 92 | $92,292 |
| XphozahTenapanor Hcl | 18 | $48,273 |
| AuryxiaFerric Citrate | 13 | $44,495 |
| LokelmaSodium Zirconium Cyclosilicate | 38 | $43,666 |
| VeltassaPatiromer Calcium Sorbitex | 33 | $42,536 |
| Sevelamer Carbonate | 56 | $28,886 |
| JardianceEmpagliflozin | 23 | $24,593 |
| InvokanaCanagliflozin | 14 | $22,376 |
| Tolvaptan | 12 | $21,731 |
| Lanthanum Carbonate | 13 | $17,177 |
| AranespDarbepoetin Alfa In Polysorbat | 11 | $15,784 |
| JanuviaSitagliptin Phosphate | 11 | $9,663 |
| Cinacalcet Hcl | 28 | $7,696 |
| Calcium Acetate | 18 | $3,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $818 | $236,89312 claims |
| AstraZenecaFarxiga, Lokelma | $1,422 | $135,958130 claims |
| Akebia Therapeutics IncAuryxia | $437 | $44,49513 claims |
| Boehringer IngelheimJardiance | $328 | $24,59323 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $16 | $21,73112 claims |
| AmgenAranesp | $717 | $15,78411 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $17 | $2,22863 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 325 nephrology providers in Michigan.
Other nephrology in Livonia
- Crystal Gardner-MartinLivonia$140K
- Mark MarroneLivonia$8K
- Victoria GolasLivonia$6K
- Jason BiedermanLivonia$6K
- Kelly MercierLivonia$6K
- Talanki ViswanathLivonia$5K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Katherine KwonSaint Joseph$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.